Ligand Pharmaceuticals Incorporated(LGND)Earnings, Financials & Key RatiosLigand Pharmaceuticals Incorporated (LGND) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company maintains a high current ratio of 21.28, the extreme volatility in free cash flow margins, which ranged from negative 56.8% to 93.7% over the last five quarters, warrants a wait-and-see approach regarding long-term operational stability.
Ligand Pharmaceuticals Incorporated (LGND) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Ligand Pharmaceuticals Incorporated (LGND) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $1.63vs $1.84-11.4% | $52Mvs $59M-12.5% |
| Q1 2026 | Feb 26, 2026 | $2.02vs $1.46+38.4% | $60Mvs $56M+7.3% |
| Q4 2025 | Nov 6, 2025 | $3.09vs $1.97+56.9% | $115Mvs $56M+107.7% |
| Q3 2025 | Aug 7, 2025 | $1.60vs $1.54+3.9% | $48Mvs $53M-9.9% |
Recent stock market news and headlines for Ligand Pharmaceuticals Incorporated (LGND)
Ligand Pharmaceuticals has delivered exceptional long-term returns, rising from ~$86 to nearly $300 over six years. Recent developments include a significant Xoma acquisition and portfolio advancements. I closely review LGND's Q1 2026 earnings, highlighting operational and financial performance and strategic moves.
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand's common stock upon conversion of the notes JUPITER, Fla., June 25, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.00% convertible senior notes due 2031 (the “notes”).
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand's common stock upon conversion of the notes JUPITER, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $625.0 million aggregate principal amount of 0.0% convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand's common stock upon conversion of the notes JUPITER, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $550.0 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors.
Key metrics vs top competitors for Ligand Pharmaceuticals Incorporated (LGND)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $319.43 | $6.4B | 52.11 | 60.4% | 46.42% | 13.47% | — | |
| $11.19 | $1.55B | -1.09 | -2.75% | -43.5% | -50.65% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $107.17 | $5.17B | 16.89 | 5.91% | 32.63% | 49.18% | — | |
| $57.80 | $24.76B | 32.11 | 5.06% | 33.9% | 8.54% | — | |
| $4.38 | $303.37M | -1.39 | 105.77% | -344.95% | -35.74% | — |
Ligand Pharmaceuticals Incorporated (LGND) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Ligand Pharmaceuticals Incorporated (LGND) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 18, 2026·SEC
May 7, 2026·SEC
Apr 30, 2026·SEC
Get notified when LGND posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ligand Pharmaceuticals Incorporated (LGND) stock FAQ — growth, dividends, profitability & financials explained
Ligand Pharmaceuticals Incorporated (LGND) reported $274.5M in revenue for fiscal year 2025. This represents a 646% increase from $36.8M in 1996.
Ligand Pharmaceuticals Incorporated (LGND) grew revenue by 60.4% over the past year. This is strong growth.
Yes, Ligand Pharmaceuticals Incorporated (LGND) is profitable, generating $153.6M in net income for fiscal year 2025 (46.4% net margin).
Ligand Pharmaceuticals Incorporated (LGND) has a return on equity (ROE) of 13.5%. This is reasonable for most industries.
Ligand Pharmaceuticals Incorporated (LGND) generated $123.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
